Sugi Predict

Sugi Predict / Compounds / SCHEMBL489493

SCHEMBL489493

SCHEMBL489493

CCOC(=O)[C@H](CCSC)NC(=O)[C@@H](CSC(C)=O)Cc1ccccc1C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MME P08473 1/20 0.46
▸ ANPEP P15144 1/20 0.46
▸ PPID Q08752 1/20 0.45
▸ CYP3A4 P08684 2/20 0.41
▸ CYP2C19 P33261 2/20 0.41
▸ LTA4H P09960 1/20 0.41
▸ GAA P10253 1/20 0.40
▸ CYP1A2 P05177 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ ABCC3 O15438 1/20 0.39
▸ NR1I2 O75469 1/20 0.39
▸ ABCB11 O95342 1/20 0.39
▸ NR3C1 P04150 1/20 0.39
▸ RARG P13631 1/20 0.39
▸ CNR1 P21554 1/20 0.39
▸ OPRK1 P41145 1/20 0.39
▸ NR1H2 P55055 1/20 0.39
▸ PPARA Q07869 1/20 0.39
▸ NR1H3 Q13133 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29436986 1.00 MME (0.46) MMEANPEPPPIDCYP3A4CYP2C19
SCHEMBL29977652 1.00 MME (0.46) MMEANPEPPPIDCYP3A4CYP2C19
SCHEMBL389351 1.00 MME (0.46) MMEANPEPPPIDCYP3A4CYP2C19
SCHEMBL29436985 1.00 MME (0.46) MMEANPEPPPIDCYP3A4CYP2C19
SCHEMBL389352 1.00 MME (0.46) MMEANPEPPPIDCYP3A4CYP2C19
SCHEMBL7431612 0.93 CYP3A4 (0.48) MMEANPEPCYP3A4CYP2C19GAA
SCHEMBL7431614 0.93 CYP3A4 (0.48) MMEANPEPCYP3A4CYP2C19GAA
SCHEMBL28000637 0.90 MME (0.47) MMEANPEPPPIDCYP3A4CYP2C19
SCHEMBL21239953 0.89 LTA4H (0.53) MMEANPEPLTA4H
SCHEMBL21239952 0.89 LTA4H (0.53) MMEANPEPLTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 349 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240016813-A1 METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION Accencio LLC 2024-01-18 — — US claimed
WO-2022056115-A1 METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION Accencio LLC (US) 2022-03-17 — — WO claimed
WO-1993011797-A1 DRUG CONTAINING AN ATRIOPEPTIDASE INHIBITOR AND AT LEAST ONE CALCIC ANTAGONIST SOCIETE CIVILE BIOPROJET (FR) 1993-06-24 — — WO claimed
US-4929641-A DIURETICS, ANGIOTENSIN CONVERTING ENZYMES SCHERING CORPORATION (US) 1990-05-29 — — US claimed
US-12351561-B2 Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof THERAVANCE BIOPHARMA R&D IP, LLC (US) 2025-07-08 — — US disclosed
CN-113166204-B Cyclic peptides as inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK 9) for the treatment of metabolic disorders 诺华股份有限公司 2025-01-28 — — CN disclosed
US-12209144-B2 Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders NOVARTIS AG (CH) 2025-01-28 — — US disclosed
CN-113166114-B Cyclic tetramer compounds as inhibitors of proprotein convertase subtilisin/KEXIN type 9 (PCSK 9) for the treatment of metabolic disorders 诺华股份有限公司 2025-01-03 — — CN disclosed
US-20240327360-A1 CRYSTALLINE (2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF THERAVANCE BIOPHARMA R&D IP LLC (US) 2024-10-03 — — US disclosed
US-12083099-B2 Methods of treating symptoms of coronavirus infection with viral protease inhibitors Accencio LLC (US) 2024-09-10 — — US disclosed
US-12016835-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2024-06-25 — — US disclosed
US-20240165032-A1 DRUG DELIVERY SYSTEM EB IP HYBRITABS B V (NL) 2024-05-23 — — US disclosed
US-20090023228-A1 Dual-acting Imidazole antihypertensive agents THERAVANCE, INC. 2009-01-22 — — US disclosed
US-20080318951-A1 Dual-acting benzoimidazole antihypertensive agents THERAVANCE, INC. 2008-12-25 — — US disclosed
US-20080269305-A1 R)-N-{2-Butyl-3-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl]-3H-imidazol-4-ylmethyl}-2-(2-hydroxycarbamoyl-3-phenyl-propionylamino)succinamic Acid; AT1 receptor antagonist and neprilysin (NEP) enzyme inhibition activity; hypertension, heart failure THERAVANCE, INC. 2008-10-30 — — US disclosed
US-20080188533-A1 2-Mercaptomethyl-4-methylpentanoic Acid (2-Butyryl-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]aminoethyl)amide THERAVANCE BIOPHARMA R&D IP, LLC 2008-08-07 — — US disclosed
EP-0528997-B1 DISULFIDE DERIVATIVES OF MERCAPTOACYLAMINO ACIDS SCHERING CORP (US) 1995-02-01 — — EP disclosed
WO-1993011797-A1 DRUG CONTAINING AN ATRIOPEPTIDASE INHIBITOR AND AT LEAST ONE CALCIC ANTAGONIST SOCIETE CIVILE BIOPROJET (FR) 1993-06-24 — — WO disclosed
WO-1993010773-A1 USE OF NEUTRAL ENDOPEPTIDASE INHIBITORS IN THE TREATMENT OF LEFT VENTRICULAR HYPERTROPHY SCHERING-PLOUGH S.P.A. (IT) 1993-06-10 — — WO disclosed
WO-1991017980-A1 DISULFIDE DERIVATIVES OF MERCAPTOACYLAMINO ACIDS SCHERING CORPORATION (US) 1991-11-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269305-A1 R)-N-{2-Butyl-3-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl]-3H-imidazol-4-ylmethyl}-2-(2-hydroxycarbamoyl-3-phenyl-propionylamino)succinamic Acid; AT1 receptor antagonist and neprilysin (NEP) enzyme inhibition activity; hypertension, heart failure AGTR2, REN, AGTR1 MME 4/4885ANPEP 38/4885PPID 4076/4885
US-12351561-B2 Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof MME, CTSC, REN MME 1/4885ANPEP 13/4885PPID 2569/4885
US-20240327360-A1 CRYSTALLINE (2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF MME, CTSC, REN MME 1/4885ANPEP 13/4885PPID 2569/4885
US-20090023228-A1 Dual-acting Imidazole antihypertensive agents AGTR1, AGTR2, REN MME 13/4885ANPEP 192/4885PPID 2834/4885
US-20240016813-A1 METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION ACE2, ACE, TMPRSS2 MME 7/4885ANPEP 16/4885PPID 1891/4885
US-12083099-B2 Methods of treating symptoms of coronavirus infection with viral protease inhibitors ACE, ACE2, TMPRSS2 MME 4/4885ANPEP 12/4885PPID 2019/4885
US-20080188533-A1 2-Mercaptomethyl-4-methylpentanoic Acid (2-Butyryl-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]aminoethyl)amide MME, AGTR1, AGTR2 MME 1/4885ANPEP 20/4885PPID 4608/4885
US-12209144-B2 Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders PCSK9, PCSK7, PCSK6 MME 125/4885ANPEP 233/4885PPID 757/4885
US-12016835-B2 Neprilysin inhibitors MME, REN, ACE MME 1/4885ANPEP 7/4885PPID 3182/4885
US-20080318951-A1 Dual-acting benzoimidazole antihypertensive agents AGTR1, REN, AGTR2 MME 6/4885ANPEP 94/4885PPID 3669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.